Sounds like Richard Pazdur, head of Oncology Cente
Post# of 155133
If Dr. Prasad, the oncologist & biostatician, is directly handling Leronlimab's path, which i do not see why he would not be, given our data, then that would be excellent.
Excited, frustrated, irritatable, impatient -- shareholder
But sayin it again:
We just might score one hell of an outstanding FDA press release.....

